A Phase II Study of LBH589 in the Treatment of Patients With Refractory Clear Cell Renal Carcinoma.

Trial Profile

A Phase II Study of LBH589 in the Treatment of Patients With Refractory Clear Cell Renal Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2013

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 May 2011 Planned End Date changed from 1 Jan 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 02 Nov 2010 Planned End Date changed from 1 Jan 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
    • 12 Mar 2010 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top